Warning: Use of undefined constant ‘ALLOW_UNFILTERED_UPLOADS’ - assumed '‘ALLOW_UNFILTERED_UPLOADS’' (this will throw an Error in a future version of PHP) in /home/psychcon/public_html/wp-config.php on line 57
Spravato - Psychiatric Consultants of Wichita
Spravato™ nasal spray

Spravato™ (esketamine) CIII - Nasal Spray

Spravato™ is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.

Spravato™ is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if Spravato™ is safe or effective as an anesthetic medicine.

It is not known if Spravato™ is safe and effective in children.

SPRAVATO™ Frequently asked questions

Spravato™ (esketamine) CIII nasal spray is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.

Spravato™ targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that Spravato™ works is unknown. Spravato™ is taken with a daily oral antidepressant.

Doctors may define the term treatment-resistant depression differently. In the Spravato™ clinical trials, treatment-resistant depression was defined as adults who are currently struggling with major depressive disorder and have not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode.

The safety and benefits of Spravato™ nasal spray, given with an oral antidepressant, were studied in a clinical program involving short- and long-term trials across more than 1,700 adult patients with treatment-resistant depression that compared Spravato™ plus an oral antidepressant to a placebo nasal spray plus an oral antidepressant. These studies evaluated the efficacy and safety of Spravato™, both short-term and long-term for up to one year, for treatment‑resistant depression.

Talk to your doctor to see if Spravato™ may be right for you. Spravato™ is a prescription medicine given by nasal spray and taken with an oral antidepressant to improve the symptoms of depression in adults who have treatment-resistant depression. Be sure to tell your doctor if you have a history of abusing prescription or street drugs, or a problem with alcohol. You should also tell your doctor if you are pregnant, planning to become pregnant, are breastfeeding or planning to breastfeed. Do not take Spravato™ if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or are allergic to esketamine, ketamine or any of the ingredients in Spravato™. Talk to your doctor about all of your health conditions and medicines when discussing treatment with Spravato™.

Spravato™ (esketamine) CIII nasal spray is a derivative of ketamine. Spravato™ is an FDA-approved nasal spray for treatment-resistant depression. Intravenous (IV) ketamine has not been approved by the FDA to treat depression. Both Spravato™ and ketamine are Schedule III controlled substances under the U.S. Controlled Substances Act.

The team at your certified Spravato™ treatment center may be able to assist you in determining your specific insurance coverage for Spravato™ and potential out-of-pocket costs of treatment. Janssen CarePath can also help in reviewing with you and your healthcare professional your health plan benefits, insurance coverage and out-of-pocket costs.

To learn more about your insurance coverage for Spravato™ and other resources, please call a Janssen CarePath Care Coordinator at 844-777-2828 or visit JanssenCarePath.com.

Spravato™ nasal spray